At a glance
- Originator Genelabs Technologies
- Class Antithrombotics; Vascular disorder therapies
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Deep vein thrombosis; Embolism; Thrombosis; Unstable angina pectoris